Improvement of Laboratory Diagnostics in Hypothyroid Patients Using Levothyroxine

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

About this trial

Hypothyroidism is a thyroid disorder and one of the most common endocrine disorders. Hypothyroidism can have multiple causes; most patients suffer from primary autoimmune hypothyroidism (Hashimoto's disease), but also central hypothyroidism, hypothyroidism after total thyroidectomy due to thyroid carcinoma, or hypothyroidism due to therapy of Graves' disease occur. Most patients with hypothyroidism are treated with levothyroxine (L-T4) to supplement the lack of thyroxine (T4) produced by their own thyroid. Serum thyroid-stimulating hormone (TSH) and/or free T4 (fT4) are currently measured to assess the efficacy of this therapy and to establish euthyroidism. It is known that fT4 concentrations in patients using L-T4 can be above the upper limit of the reference interval, while their TSH is not (completely) suppressed. This raises the question whether fT4 is an accurate reflection of thyroid hormone status in patients using L-T4. TSH is considered a reliable parameter of thyroid hormone status; however, TSH cannot be used to assess thyroid function in specific hypothyroid patient groups (e.g. central hypothyroidism). Free triiodothyronine (fT3), the active thyroid hormone, has been suggested to be an interesting alternative of fT4 to assess thyroid function. Previously, the methods to measure fT3 were not that robust; however, methods to determine fT3 have been improved, are currently reliable and not susceptible to changes due to L-T4 intake. In addition, the fT3/fT4 ratio is thought to be an interesting candidate in assessing thyroid hormone status as well. The aim of this study is to improve laboratory diagnostics of thyroid hormone status in patients with hypothyroidism receiving L-T4 in whom TSH cannot be used as a reflection of thyroid hormone status. We will primarily investigate the additional already available laboratory tests fT3 and fT3/fT4 ratio. We hypothesize that treated hypothyroid participants who are assumed euthyroid based on TSH (e.g. patients with Hashimoto's hypothyroidism) but have fT4 concentrations above the upper reference limit will more often have a fT3 level or a fT3/fT4 ratio within the reference interval. Concentrations of alternative markers in healthy controls and patients with Hashimoto's hypothyroidism with 'normal' TSH concentrations can, thus, be used to predict thyroid hormone status in patients using L-T4 in whom TSH cannot be used to assess thyroid hormone status.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Ability to provide informed consent

Ability to speak and understand Dutch or English

Intake of a stable dosage of levothyroxine, meaning the dosage of levothyroxine must not be changed during the appointment at the outpatient clinic

Diagnosis of one these forms of hypothyroidism

Disqualifiers

Not euthyroid according to physician

Pregnancy

Patients using L-T4 due to therapy of Graves' disease: if TSH is still suppressed

Any of the following medication

Trial population

Adults with hypothyroidism using levothyroxine (L-T4) attending the outpatient clinic of Amsterdam UMC will be included. Healthy euthyroid controls will be recruited amongst employees of Amsterdam UMC.

Trial design

Design model

Other

Time perspective

Cross-sectional

Treatments tested in this trial

  • Single extra blood draw and completion of single questionnaire

    Other intervention

    Single blood draw of 3 tubes (20 mL) additional to regular blood draw will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.

  • Single blood draw and completion of single questionnaire

    Other intervention

    Single blood draw of 3 tubes (20 mL) will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.

Treatment groups

500 Participants
are divided into 5 treatment groups
Group A: Hashimoto's hypothyroidism1 intervention
Group B: Hypothyroidism after thyroidectomy after thyroid carcinoma1 intervention
Group C: Central hypothyroidism1 intervention
Group D: Hypothyroidism during treatment for Graves' Disease1 intervention
Group E: Healthy controls1 intervention

Trial outcomes

Primary outcomes

1

TSH concentration

Laboratory measurement

Time frame
Single measurement in cross-sectional design during the study period, which is approximately 4 years
2

fT4 concentration

Laboratory measurement

Time frame
Single measurement in cross-sectional design during the study period, which is approximately 4 years
3

fT3 concentration

Laboratory measurement

Time frame
Single measurement in cross-sectional design during the study period, which is approximately 4 years
4

fT3/fT4 ratio

Ratio derived from abovementioned laboratory measurements

Time frame
One-time determination in cross-sectional design during the study period, which is approximately 4 years

Secondary outcomes

1

TT4 concentration

Laboratory measurement

Time frame
Single measurement in cross-sectional design during the study period, which is approximately 4 years
2

TT3 concentration

Laboratory measurement

Time frame
Single measurement in cross-sectional design during the study period, which is approximately 4 years
3

rT3 concentration

Laboratory measurement

Time frame
Single measurement in cross-sectional design during the study period, which is approximately 4 years
4

SHBG

Laboratory measurement

Time frame
Single measurement in cross-sectional design during the study period, which is approximately 4 years

Other outcomes

1

ThyPRO-39

Questionnaire

Time frame
One-time completion around time of laboratory measurement during the study period, which is approximately 4 years
2

DIO polymophisms

Laboratory measurement

Time frame
Single measurement in cross-sectional design during the study period, which is approximately 4 years
3

Sex

Questionnaire; patient characteristics

Time frame
One-time completion around time of laboratory measurement during the study period, which is approximately 4 years
4

Age

Questionnaire; patient characteristics

Time frame
One-time completion around time of laboratory measurement during the study period, which is approximately 4 years

Sponsors and contacts

Click on the lead sponsor to view all of their trials.